In appraising orphan medicines to treat rare diseases, the Scottish Medicines Consortium (SMC) may, in addition to the standard assessment of clinical and cost-effectiveness, apply modifiers which consider other additional factors. subject to meeting certain criteria, this can facilitate acceptance of a medicine notwithstanding the economic evidence provided.